Nathanael L. Dirks, Pharm.D., Ph.D.

Principal Scientist I

Nathanael joined Metrum in 2010 after receiving his Pharm.D. and Ph.D. (Pharmaceutical Sciences). In his tenure at Metrum, Nathanael has applied both clinical pharmacy knowledge and pharmacometric methods to PK/PD modeling and simulation analyses and strategic decision making at all stages of drug development. His clinical experience spans a broad range of small molecule and biologic therapeutics in a number of therapeutic areas with particular emphasis in pediatric pharmacology, rare diseases, pain management, and inflammatory diseases.

Recent publications by this scientist

Corrigendum: Exposure-efficacy relationships for vedolizumab induction therapy in patients with ulcerative colitis or Crohn’s disease

March 28, 2018

Rosario M, French JL, Dirks NL, Sankoh S, Parikh A, Yang H, Danese S, Colombel JF, Smyth M, Sandborn WJ, Feagan BG, Reinisch W, Sands BE, Sans M, Fox I. J Crohns Colitis 12 (4): 510. 2018 Mar 28.

Download PDF

Model-based clinical pharmacology profiling and exposure-response relationships of the efficacy and biomarker of lebrikizumab in patients with moderate-to-severe asthma

October 30, 2017

Zhu R, Zheng Y, Dirks NL, Vadhavkar S, Jin JY, Peng K, Holweg CTJ, Olsson J, Matthews JG, Putnam WS. Pulmonary Pharmacology & Therapeutics 46: 88–98. October 2017.

Download PDF

Vedolizumab efficacy exposure–response relationship for ulcerative colitis patients (GEMINI I) based on causal inference analysis

October 1, 2016

Gastonguay MR, Lasch K, Barocas M, Rosario M, Wilbur JD, Dirks NL, Osterman MT.  Presented at the American College of Gastroenterology Annual Meeting, October, 2016.

Download PDF